A Long‐Lasting Skin Protectant Based on CG‐101, a Deep Eutectic Solvent Comprising Choline and Geranic Acid

  1. Marina Shevachman
  2. Abhirup Mandal
  3. Kevin Gelston
  4. Samir Mitragotri
  5. Nitin Joshi

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

The COVID‐19 public health crisis has spotlighted the need to improve global hygiene and sanitization. In addition to causing staggering rates of transmission and fatality, COVID‐19 has severely impacted the quality of life and mental health of global citizens. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) encourage hand hygiene as the first defense against the spread of infection, yet frequent handwashing is often impractical. Widely used ethanol‐based hand sanitizers provide immediate protection against pathogens on the skin, albeit short‐lived, due to their rapid evaporation. Herein, a novel, long‐lasting skin protectant formulated with biocompatible ionic liquid/deep eutectic solvents prepared using generally recognized as safe materials – choline and geranic acid (CG‐101, 5% w/w) – is described. In vitro studies demonstrated that CG‐101 inactivates bacteria and the human coronavirus, hCoV229E, for 4 h after application. Two human clinical studies demonstrate that CG‐101 does not cause skin irritation or sensitization, and a single application of CG‐101 gel imparts skin protection against microbes for significantly longer than conventional 70% ethanol‐based hand sanitizers. These data are the first to indicate that CG‐101 may be a better alternative to alcohol‐based hand sanitizers for long‐term skin protection against infectious diseases.

Article activity feed

  1. Version published to 10.1002/gch2.202200064
  2. ScreenIT

    SciScore for 10.1101/2020.08.04.20161067: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Experimental Models: Cell Lines
    SentencesResources
    Coronavirus (alphacoronavirus) strain 229E (ATCC #VR-740) and MRC-5 (ATCC #CCL-171; human lung fibroblast cells) were used for the study.
    MRC-5
    suggested: ATCC Cat# CCL-171, RRID:CVCL_0440)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: We found the following clinical trial numbers in your paper:

    IdentifierStatusTitle
    NCT04495920CompletedClinical Evaluation of the Residual Antimicrobial Activity
    NCT04498676Completed50 Human Subject Repeat Insult Patch Test

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a protocol registration statement.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.08.04.20161067v1 on medRxiv